Protein clumps in the brain have long been associated with Alzheimer’s, but other potential causes of the condition are now ...

But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer's disease (DIAD). Gantenerumab was associated with ...

Alzheimer’s disease is characterized by a host of recognizable cognitive symptoms, but many non-cognitive symptoms like changes in sleep, anxiety and depression can be early signs of the disease.

The brain's cholesterol regulation and metabolism mechanisms may make some neurons more vulnerable to damage in the early ...

For years, Alzheimer’s disease has been considered a brain disorder that leads to memory loss and cognitive decline. It’s a ...